Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00193154 · ClinicalTrials.gov registry record · Phase 2
OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT00193154 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 63 participants.
The verdict
NCT00193154, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
In this phase II trial, we plan to evaluate the combination of Tarceva and Avastin in the treatment of patients with metastatic renal cell carcinoma. This trial will be one of the first phase II trials to evaluate a combination of targeted agents in the treatment of a common solid tumor with a strong biologic rationale based on Cancer Biology (VHL/HIF/VEGF/EGFr).
Interventions
- DRUG Bevacizumab
- DRUG OSI-774
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2003-02 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00193154
The ClinicalTrials.gov registry entry for NCT00193154 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00193154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00193154 about?
NCT00193154 is a clinical study titled "OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma". In this phase II trial, we plan to evaluate the combination of Tarceva and Avastin in the treatment of patients with metastatic renal cell carcinoma. This trial will be one of the first phase II trials to evaluate a combination of targeted agents in the treatment of a common solid tumor with a stron...
What is the current status of trial NCT00193154?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2003-02. Estimated completion is 2014-03.
What interventions are being tested in trial NCT00193154?
The interventions under investigation include: Bevacizumab (DRUG), OSI-774 (DRUG).
Who is sponsoring clinical trial NCT00193154?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.